BIOMARKERS AND USES THEREOF IN THE TREATMENT OF CHRONIC HEPATITIS B INFECTION

摘要

Single nucleotide polymorphisms (SNPs) that are indicative of relapse after a HBV direct-acting antiviral agent (DAA) treatment, such as a NUC treatment in a chronic hepatitis B (CHB) infected subject are described. Also described are methods of using the SNPs in predicting the relapse in the HBV DAA treatment of CHB infection.